INTRODUCTION
============

Dyslipidemia, which was previously considered to only affect patients with genetic susceptibility, has now become one of the most prevalent chronic metabolic disorders. The prevalence of dyslipidemia in Korea has reached 40% in adults over 20 years of age \[[@B1]\]; consequently, the use of lipid-modifying drugs has increased rapidly \[[@B2]\]. The role of low-density lipoprotein cholesterol (LDL-C) in the formation of atherosclerosis, development of therapeutic agents acting on the LDL receptor, and success of large clinical trials of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) has significantly affected the current paradigm of "lowering LDL-C levels using statins" for reduction of cardiovascular risk \[[@B3][@B4][@B5]\]. Although this is still "the era of statins," recent clinical and epidemiological studies have noted the residual risk of cardiovascular disease (CVD) that statins do not manage, and some studies have demonstrated the potential role of non-statin drugs in the management of residual cardiovascular risk \[[@B6][@B7]\]. Fibrates are lipid-modifying drugs that act mainly to elevate triglycerides (TG) and lower the levels of high-density lipoprotein cholesterol (HDL-C). Early clinical trials of fibrates were promising, but their role in cardiovascular risk management has gradually diminished in the statin era. The major guidelines also limited the use of fibrates to adults with severe hypertriglyceridemia (fasting TG ≥500 mg/dL) or those at high cardiovascular risk with hypertriglyceridemia only in combination with statins \[[@B8][@B9]\].

However, recent studies have demonstrated that fibrate drugs, particularly fenofibrate, have a therapeutic role in dyslipidemia, especially in patients with metabolic syndrome traits. Here, we have reviewed recent data on fibrates and discussed the appropriate use of fibrates in clinical practice.

PHARMACOLOGIC ACTION OF FIBRATES
================================

Fibrates have been used as clinical treatments since the 1960s; however, it was not until the early 1990s that their mechanism of action was identified. Fibrates have multiple pharmacological actions, mainly as a synthetic ligand for the peroxisome proliferator-activated receptors (PPARs), especially PPARα. PPARs belong to a family of nuclear receptors known to regulate carbohydrate and lipid metabolism and adipocyte differentiation \[[@B10]\]. When a ligand binds to PPAR, it induces conformational changes that allow the recruitment of coactivators. Subsequently, PPAR forms a heterodimer with another nuclear receptor, the retinoid X receptor (RXR) \[[@B11]\]. The complex recognizes and binds to PPAR response elements (PPREs) in the promoter region of the target genes and regulates the expression of various genes. The lipid-modifying activity of fibrate occurs mainly through PPARα activation. Clinically, fibrates reduce plasma TG or TG-rich lipoproteins (TRLs) and increase HDL concentration through various PPARα actions, including: (1) increased lipolysis via lipoprotein lipase (LPL) activation and ApoC-III suppression \[[@B12][@B13]\]; (2) increased hepatic fatty acid uptake through fatty acid transporter protein (FATP) and acyl-coA synthetase induction \[[@B14][@B15]\]; and (3) increased ApoA-I and ApoA-II synthesis \[[@B16]\]. In addition, fibrates were found to have anti-atherogenic effects through reduction in vascular cell adhesion molecule (VCAM) and monocyte chemoattractant protein-1 (MCP-1) \[[@B17]\], and anti-inflammatory effects were identified to occur through the reduction of the expression of various proinflammatory genes and inflammatory markers \[[@B18]\].

RESIDUAL RISK OF CARDIOVASCULAR DISEASE AND THE ROLE OF ATHEROGENIC DYSLIPIDEMIA
================================================================================

Currently, the major guidelines for dyslipidemia management recommend statin treatment for most cardiovascular risk groups \[[@B2][@B8][@B9]\]. The LDL-C target differs by guideline, but it is conventionally recommended to stay below 100 mg/dL in the high risk group and below 70 mg/dL in the very high risk group of CVD. One of the unresolved issues is the continued significant risk of CVD despite adequate statin treatments \[[@B6][@B19]\]. Therefore, the methods of measuring and managing this residual cardiovascular risk remains an important issue. There is considerable evidence from the *post hoc* analyses of major randomized controlled trials (RCTs) of statins or meta-analyses for the assessment and prediction of residual cardiovascular risk. Although there is no consensus yet, lipid or lipoprotein parameters, such as non-HDL-C \[[@B20]\], TG \[[@B21]\], HDL-C \[[@B22]\], small very low-density lipoprotein (VLDL) particles \[[@B23]\], and the ApoB/A-I ratio \[[@B24]\], have been verified as the predictors. Among these, a number of studies have focused on the traits of atherogenic dyslipidemia (elevated TG, and small dense LDL particles with a low level of HDL-C), which are components of metabolic syndrome and are directly related to insulin resistance \[[@B25]\]. Both on-treatment HDL-C level in the *post hoc* analysis of the Treating to New Targets (TNT) trial \[[@B22]\] and on-treatment TG level in the Pravastatin or Atorvastatin Evaluation and Infection Trial (PROVE IT) trial \[[@B21]\] were identified as independent predictors of the residual risk of CVD. In addition, similar results were obtained from the Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin With Terutroban in Patients With a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) and the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) studies \[[@B26]\] and a meta-analysis study \[[@B27]\]. In the statin era, atherogenic dyslipidemia is not just a phenotype of metabolic syndrome or insulin resistance, but also a predictor of future CVD and a medical state to be managed.

Therefore, research into the clinical effects of drugs that directly affect TG and HDL-C, including niacin, fibrates, n-3 fatty acids, and cholesteryl ester transfer protein (CETP) inhibitors, has continued. In the early 2010s, the use of these non-statin drugs was viewed skeptically, based on large-scale RCTs that showed no reduction in major cardiovascular events when added to statins \[[@B28][@B29][@B30][@B31][@B32][@B33]\]. However, more recent evidence has identified results that may combat this skepticism; these are described elsewhere \[[@B7][@B34]\]. In this review, we have focused on the details of fibrate research.

CLINICAL TRIALS OF FIBRATES
===========================

The history of cardiovascular outcome trials (CVOTs) of fibrate drugs dates back to 1987 ([Table 1](#T1){ref-type="table"}). The Helsinki Heart Study (HHS) evaluated the effects of gemfibrozil on major CVD in 4,081 patients with dyslipidemia 7 years earlier than the Scandinavian Simvastatin Survival Study (4S), which was the first CVOT of statins \[[@B35]\]. The HHS included asymptomatic middle-aged men with primary dyslipidemia (non-HDL-C ≥200 mg/dL) without CVD. The primary endpoint was fatal and nonfatal myocardial infarction (MI) and cardiac death. The results showed that gemfibrozil significantly reduced the primary endpoints by 34% compared with placebo. Subsequently, the Veterans Affairs HDL Intervention Trial (VA-HIT) study, a secondary prevention trial, confirmed the benefit of gemfibrozil on cardiovascular risk reduction in patients with coronary heart disease (CHD), either \[[@B36]\]. However, the two outcome trials of bezafibrate, the Bezafibrate Infarction Prevention (BIP) study and the Lower Extremity Arterial Disease Event Reduction (LEADER) study, failed to demonstrate cardiovascular risk reduction compared with placebo \[[@B37][@B38]\]. The characteristics of participants in the two bezafibrate studies were similar to those of the VA-HIT trial as secondary prevention trials. Thus, a few possible explanations were suggested for the different results between gemfibrozil and bezafibrate studies. Higher rate of use of open-label lipid modification drugs in the placebo group than bezafibrate group was noted explaining the negative results of the BIP and LEADER trials. In part, the lower TG lowering efficacy of bezafibrate than gemfibrozil (21% reduction in the BIP, 23.3% in the LEADER, and 31% in the VA-HIT) was also indicated. On the other hand, in the subgroups of patients with high blood TG and low HDL-C levels in the BIP study, a significant 41.8% reduction was identified in the primary outcome, suggesting that the drug could have a beneficial effect in patients with atherogenic dyslipidemia.

In 2005, the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, the first CVOT of fenofibrate as well as the first fibrates study exclusively for type 2 diabetes mellitus patients, was published \[[@B39]\]. Nine thousand seven hundred ninety-five patients with type 2 diabetes mellitus not taking statins at study entry were included. The primary endpoint was CHD death or non-fatal MI. As a result, this study did not show the cardiovascular benefits of fenofibrate compared with placebo; a non-significant 11% reduction in the primary endpoint (hazard ratio \[HR\], 0.89; 95% confidence interval \[CI\], 0.75 to 1.05; *P*=0.16). At the end of the study, it was suggested that the effects of the study drug may have been masked by almost double the use of lipid-lowering agents other than fenofibrate in the placebo group (36% vs. 19%). Smaller reduction of HDL-C than expected and increase in plasma homocysteine concentration with fenofibrate therapy were also suggested as possible reason for the non-significant results although they only explained in part. The subsequent fenofibrate CVOT, the Action to Control Cardiovascular Risk in Diabetes (ACCORD)-Lipid trial, aimed to demonstrate the additional benefits of fenofibrate add-on to statins in patients with type 2 diabetes mellitus \[[@B33]\]. Finally, there was no significant difference in the primary outcome between groups, but like as in the BIP study, a substantial risk reduction by 28.6% was observed in the subgroup of patients with low HDL-C (≤34 mg/dL) and high TG (≥204 mg/dL). In 2017, a post-trial observation of the ACCORD-Lipid trial, the ACCORD Follow-On (ACCORDION) study, was published \[[@B40]\]. During a follow-up period of 9.7 years, the main results were not different from the primary ACCORD-Lipid results. Interestingly, although only 4.3% of patients continued to take fenofibrate after the end of the original ACCORD-Lipid study, the cardiovascular benefits in the original fenofibrate group with atherogenic dyslipidemia were maintained. Several meta-analyses of fibrate drugs or fenofibrate also have proven that fibrates reduce the cardiovascular risk in patients with atherogenic dyslipidemia or metabolic syndrome \[[@B41][@B42][@B43]\].

Collectively, RCT-based evidence of fibrates in terms of cardiovascular risk reduction seemed not to be consistent. It is still unclear that each individual drugs in fibrate class are different in nature and efficacy. Nevertheless, previous findings in together suggested that fibrates have a possible beneficial role in cardiovascular risk reduction in specific population, especially in patients with an atherogenic dyslipidemia pattern that is closely associated with metabolic syndrome and insulin resistance. As a result, the use of fibrates in those populations, including patients with type 2 diabetes mellitus and atherogenic dyslipidemia, is recommended in many, but not all, guidelines \[[@B2][@B44][@B45]\].

REAL WORLD EVIDENCE OF FIBRATES
===============================

In recent years, real-world evidence (RWE) analysis has been actively conducted, along with large-scale population-based cohort construction. The research value of RWE begins at the limits of RCTs. RCTs provide the highest level of evidence in medical science, but the inevitable limitations of RCTs include limited patient population and the trial environment, which is hard to reproduce in the real world. Thus, it is still unclear whether results seen in RCTs can be reproduced in real-world clinical practice. Nowadays, the level of evidence A includes one or more RCTs corroborated by high-quality registry studies \[[@B17]\], recognizing the value of RWE.

The first RWE of fenofibrate, the Three-City Study, was published in 2015 \[[@B46]\]. This was a prospective cohort study of 7,484 elderly patients that compared major cardiovascular outcomes (CHD and stroke) in patients treated with fibrates, statins, and non-lipid-lowering therapy. Both the statin and fibrate groups showed a reduction of approximately 30% in stroke risk compared with the control group. Recently, we conducted a propensity score (PS)-weighted cohort study, the Effectiveness of Fenofibrate Therapy in Residual Cardiovascular Risk Reduction in the Real World Setting (ECLIPSE-REAL) study, on this issue \[[@B47]\]. This study was designed based on the ACCORD-Lipid trial, but adapted to consider the lessons from this failed trial to prove additional benefits of fenofibrate add-on to statins. From the original cohort of the Korean National Health Insurance Service-Health Screening Cohort (NHIS-HEALS), adults with metabolic syndrome who were the most appropriate candidate for fenofibrate therapy were selected. Subsequently, PS matching was performed for those who were treated with fenofibrate (combined statin plus fenofibrate group) and those who were not (statin monotherapy group). The primary outcome was the major adverse cardiovascular events (MACE) including CHD, ischemic stroke, and cardiovascular death. The primary outcome results by different PS matching population is shown in [Fig. 1](#F1){ref-type="fig"}. In the first matching cohort, based on LDL-C, HDL-C, and TG levels, the primary outcome was significantly reduced by 26% in the fenofibrate group (HR, 0.74; 95% CI, 0.58 to 0.93). To better capture the TG-lowering effect on TRLs, a sensitivity analysis was performed on the second cohort matched based on non-HDL-C levels. The results were almost same as those of primary cohort (HR, 0.77; 95% CI, 0.62 to 0.96 for MACE). In the atherogenic dyslipidemia subgroup, as defined by the ACCORD-Lipid trial, the risk of MACE was reduced by 36% with fenofibrate treatment.

The ECLIPSE-REAL study was carefully conducted to exclude important biases such as immortal and time lag biases, recently issued by observational studies \[[@B48]\], nonetheless, a definitive trial of fibrate therapy is still needed for a clearer conclusion. Currently, the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study, the CVOT of the selective PPARα modulator pemafibrate, is in progress \[[@B49]\]. This study included patients with type 2 diabetes mellitus with a TG level of 200 mg/dL or more, and an HDL-C level of 40 mg/dL or less. It is expected that the results will provide strong evidence for the efficacy of fibrate drugs, considering that the population comprised the optimal candidates for fibrate therapy.

FIBRATES IN METABOLIC SYNDROME
==============================

How can the beneficial effects of fibrates be explained in patients with metabolic syndrome, especially with atherogenic dyslipidemia? First, the lipid modification activity of fenofibrate is dependent on the baseline TG level. Higher baseline TG levels lead to a greater TG lowering efficacy of fenofibrate \[[@B50][@B51]\]. Even the elevation of HDL-C level by fenofibrate was prominent in patients with hypertriglyceridemia \[[@B52]\]. Therefore, patients with metabolic syndrome and altered lipid metabolism may respond well to fibrate therapy. Second, the complementary and synergistic effect of statins and fenofibrate could be partly attributed to the cardiovascular benefit of fibrates in metabolic syndrome. In a kinetics study, atorvastatin and fenofibrate were found to influence lipoprotein particles and apolipoprotein flux in a complementary manner; the increase in ApoA-I flux and levels due to fenofibrate and the increase in the catabolic rate of ApoB due to atorvastatin both contribute to anti-atherogenic effects \[[@B53]\]. This has been confirmed in clinical studies. Combination therapy with simvastatin and fenofibrate significantly increased the large to small dense LDL ratio compared with simvastatin alone \[[@B54]\]. Third, fibrates were found to have their own anti-inflammatory actions, independent of their lipid-modifying activity. Fenofibrate therapy induced a decrease in the levels of circulating inflammatory markers and oxidative stress markers, and an increase in the levels of adiponectin, especially in patients with metabolic syndrome \[[@B55][@B56]\].

CONCLUSIONS
===========

We presented a brief review of the evidence supporting the role of atherogenic dyslipidemia in cardiovascular risk prediction and the potential role of fibrates in cardiovascular risk reduction in patients with metabolic syndrome. The newly evolving evidence generally supports the value of fibrates in cardiovascular risk management and the need for well-designed CVOT focused on subjects with metabolic syndrome or atherogenic dyslipidemia. In conclusion, fibrate therapy would be considered as the optimal strategy for cardiovascular risk management in patients whose residual cardiovascular risk is expected to be moderate to high, even when treated with appropriate statin therapy, especially those with hypertriglyceridemia and/or low HDL-C level.
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###### Major clinical trials and epidemiological studies of fibrates
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                            Study type       Population            No.      Study drug                                Comparator                Primary outcome                                        Results                                                         Additional findings
  ------------------------- ---------------- --------------------- -------- ----------------------------------------- ------------------------- ------------------------------------------------------ --------------------------------------------------------------- ---------------------------------------------------------------
  HHS (1987)                RCT              Dyslipidemia          4,081    Gemfibrozil 1,200 mg/day                  Placebo                   Fatal and non-fatal MI or cardiac death                34%^a^reduction                                                 
  VA-HIT (1999)             RCT              CHD                   2,531    Gemfibrozil 1,200 mg/day                  Placebo                   Non-fatal MI or coronary death                         22%^a^reduction                                                 
  BIP (2000)                RCT              CHD                   3,090    Bezafibrate 400 mg/day                    Placebo                   Fatal or nonfatal MI or sudden death                   9.4% reduction (NS)                                             41.8% reduction in subgroup (HDL-C \<35 mg/dL, TG ≥200 mg/dL)
  LEADER (2002)             RCT              Lower PAD             1,568    Bezafibrate 400 mg/day                    Placebo                   CHD or stroke                                          4% reduction (NS)                                               40% reduction of non-fatal CHD
  FIELD (2005)              RCT              T2DM                  9,795    Fenofibrate 200 mg/day                    Placebo                   CHD death or non-fatal MI                              11% reduction (NS)                                              24% reduction of non-fatal MI
  ACCORD-Lipid (2010)       RCT              T2DM                  5,518    Simvastatin plus fenofibrate 160 mg/day   Simvastatin               Non-fatal MI, non-fatal stroke, cardiovascular death   8% reduction (NS)                                               28.6% reduction in subgroup (HDL-C ≤34 mg/dL, TG ≥204 mg/dL)
  ACCORDION (2017)          Post-trial f/u   T2DM                  4,644    Simvastatin plus fenofibrate 160 mg/day   Simvastatin               Non-fatal MI, non-fatal stroke, cardiovascular death   7% reduction (NS)                                               27% reduction in subgroup (HDL-C ≤34 mg/dL, TG ≥204 mg/dL)
  Three City Study (2015)   Cohort           Elderly without CVD   7,484    Statins or fibrates                       No lipid lowering drugs   CHD or stroke                                          Fibrates: 34%^a^reduction of stroke, 12% increase in CHD (NS)   
  ECLIPSE-REAL (2019)       Cohort           Metabolic syndrome    10,705   Statin plus fenofibrate 160 mg/day        Statin monotherapy        CHD, stroke, cardiovascular death                      26%^a^reduction                                                 36% reduction in subgroup (HDL-C \<34 mg/dL, TG ≥204 mg/dL)

HHS, Helsinki Heart Study; RCT, randomized controlled trial; MI, myocardial infarction; VA-HIT, Veterans Affairs HDL Intervention Trial; CHD, coronary heart disease; BIP, Bezafibrate Infarction Prevention; NS, non-significant; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; LEADER, Lower Extremity Arterial Disease Event Reduction; PAD, peripheral artery disease; FIELD, Fenofibrate Intervention and Event Lowering in Diabetes; T2DM, type 2 diabetes mellitus; ACCORD, Action to Control Cardiovascular Risk in Diabetes; ACCORDION, ACCORD Follow-On; f/u, follow-up; CVD, cardiovascular disease; ECLIPSE-REAL, Effectiveness of Fenofibrate Therapy in Residual Cardiovascular Risk Reduction in the Real World Setting.

^a^Statistically significant.
